Imatinib Eurogenerics

Imatinib, the active ingredient in Imatinib Eurogenerics, is a tyrosine kinase inhibitor presented as an oral dosage form for oral administration. It is used to treat chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Eurogenerics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, providing reliable access to this targeted anticancer therapy with consistent quality and regulatory compliance and supporting patient care across diverse health systems.

Imatinib is a tyrosine kinase inhibitor used in oncology to target specific molecular pathways. - Chronic myeloid leukemia: reduces leukemic cell proliferation and disease progression by selectively inhibiting the BCR‑ABL tyrosine kinase. - Philadelphia chromosome‑positive acute lymphoblastic leukemia: helps achieve remission by blocking the BCR‑ABL driven signaling cascade that drives malignant lymphoblast growth. - Gastrointestinal stromal tumor: controls tumor growth and metastasis by inhibiting c‑KIT and platelet‑derived growth factor receptor (PDGFR) pathways.

Imatinib may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Fatigue: generalized tiredness. - Diarrhea: loose stools. - Muscle cramps: painful involuntary contractions. - Rash: skin irritation or erythema. Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: heart failure or reduced left ventricular function. - Severe neutropenia: marked decrease in white blood cells increasing infection risk.

When prescribing Imatinib, clinicians should consider several precautionary measures to ensure patient safety. - Baseline assessment: obtain complete blood count, liver function tests and renal function before initiation. - Monitoring: regularly check CBC, hepatic enzymes and cardiac function during therapy. - Drug interactions: review concomitant medications for potential CYP3A4 modulators. - Pregnancy: avoid use unless benefits outweigh risks; discuss with obstetric specialist. - Contraindications: discontinue in patients with known hypersensitivity to imatinib or its excipients. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture and light.

Imatinib interacts with several medicines; awareness of the interaction level guides clinical management. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce imatinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase plasma concentrations and toxicity. Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may lower absorption; separate dosing by at least 2 hours. - Anticoagulants (e.g., warfarin): imatinib may enhance anticoagulant effect, requiring INR monitoring. - Live attenuated vaccines: potential reduced efficacy; assess risk‑benefit before administration.